Kabashima K, Matsumura T, Komazaki H, et al. - In patients with atopic dermatitis (AD) and inadequately controlled moderate-to-severe pruritus, administration of nemolizumab 60 mg Q4W (every 4 weeks) with concomitant topical treatments not only resulted in a continuous improvement in pruritus, signs of AD, and quality of life for up to 68 weeks, but also displayed a favorable safety profile.

• Two long-term phase III studies were conducted in which patients aged ≥13 years with AD and inadequately controlled moderate-to-severe pruritus received nemolizumab 60 mg Q4W subcutaneously, concomitantly with topical treatments.

• Study-JP01 nemolizumab/nemolizumab and placebo/nemolizumab, and Study-JP02 nemolizumab groups included 143, 72, and 88 patients, respectively.

• Clinically meaningful improvements in the pruritus visual analogue scale (66% decrease) and eczema area and severity index (78% decrease) were observed from the start of treatment to week 68, in the nemolizumab/nemolizumab group.

• Post-first nemolizumab dose, improvements were seen in quality of life indicators; improvements remained maintained during follow-up.

• The observed long-term safety profile was in line with previous reports, with no unexpected late-onset adverse events.